ANIK: Anika Therapeutics, Inc. - Summary | Jitta

Anika Therapeutics, Inc.

NASDAQ:ANIK

Price
$41.66
Loss Chance
50.6%
3.57JITTA SCORE
598.30%Over Jitta Line
Jitta Ranking
207 / 1,096
2,256 / 4,700
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (29)
Recent Business Performance (27)
Financial Strength (80)
Return to Shareholders (27)
Competitive Advantage (39)
Jitta Signs
Debt LevelLow Long Term Debt
Revenue and EarningEarning loss detected in 2020
Operating MarginDeclined
Recent Business PerformanceEarning decline 104.12% in the last year
SG&A to SalesIncreasing Every Year
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
3.57
598.30%
1.40
313.15%
2.24
459.89%
Biotechnology
6.52
52.14%
5.19
49.12%
4.83
3.22%
COMPANY DESCRIPTION
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company’s joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.